Found: 8
Select item for more details and to access through your institution.
An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 90, n. 6, p. 431, doi. 10.1007/s00280-022-04483-7
- By:
- Publication type:
- Article
A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL).
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 90, n. 6, p. 445, doi. 10.1007/s00280-022-04482-8
- By:
- Publication type:
- Article
Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 90, n. 6, p. 455, doi. 10.1007/s00280-022-04481-9
- By:
- Publication type:
- Article
Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 90, n. 6, p. 467, doi. 10.1007/s00280-022-04478-4
- By:
- Publication type:
- Article
Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic–pharmacodynamic model of neutropenia.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 90, n. 6, p. 489, doi. 10.1007/s00280-022-04484-6
- By:
- Publication type:
- Article
Absorption, distribution, metabolism, and excretion of [<sup>14</sup>C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 90, n. 6, p. 499, doi. 10.1007/s00280-022-04485-5
- By:
- Publication type:
- Article
Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 90, n. 6, p. 511, doi. 10.1007/s00280-022-04488-2
- By:
- Publication type:
- Article
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 90, n. 6, p. 523, doi. 10.1007/s00280-022-04480-w
- By:
- Publication type:
- Article